1. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection
- Author
-
Roberto Manfredi, Leonardo Calza, Francesco Chiodo, Daria Pocaterra, L. Calza, R. Manfredi, D. Pocaterra, and F. Chiodo
- Subjects
Adult ,Diarrhea ,Male ,medicine.medical_specialty ,Anti-HIV Agents ,Lopinavir/ritonavir ,HIV Infections ,Fosamprenavir ,Pyrimidinones ,Dermatology ,Pharmacology ,Drug Administration Schedule ,Lopinavir ,HIV Protease ,immune system diseases ,Abacavir ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,Pharmacology (medical) ,Treatment Failure ,Furans ,Hypertriglyceridemia ,Sulfonamides ,Ritonavir ,business.industry ,Public Health, Environmental and Occupational Health ,virus diseases ,Lamivudine ,Middle Aged ,Organophosphates ,Regimen ,Treatment Outcome ,Infectious Diseases ,Tolerability ,HIV-1 ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,Carbamates ,business ,medicine.drug - Abstract
Recent data indicate that fosamprenavir/ritonavir as part of an initial antiretroviral regimen in HIV-1 -infected patients is associated with favourable efficacy and tolerability and in the KLEAN study (kaletra versus lexiva with epivir and abacavir in antiretroviral-naive patients) it was found to be non-inferior to lopinavir/ritonavir in association with abacavir/lamivudine. In our open-label, observational study conducted in 82 therapy-naíve HIV-1-infected patients followed-up for 18 months, virological and immunological efficacy was comparable in subjects receiving a fosamprenavir/ritonavir-based and a lopinavir/ritonavir-based treatment (proportions of patients with HIV RNA
- Published
- 2008
- Full Text
- View/download PDF